Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors

BACKGROUND & AIMS: In patients with autoimmune atrophic gastritis and achlorhydria, hypergastrinemia is associated with the development of type 1 gastric neuroendocrine tumors (gNETs). Twelve months of treatment with netazepide (YF476), an antagonist of the cholecystokinin B receptor (CCKBR or C...

Descripción completa

Detalles Bibliográficos
Autores principales: Lloyd, Katie A., Parsons, Bryony N., Burkitt, Michael D., Moore, Andrew R., Papoutsopoulou, Stamatia, Boyce, Malcolm, Duckworth, Carrie A., Exarchou, Klaire, Howes, Nathan, Rainbow, Lucille, Fang, Yongxiang, Oxvig, Claus, Dodd, Steven, Varro, Andrea, Hall, Neil, Pritchard, D. Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215182/
https://www.ncbi.nlm.nih.gov/pubmed/32004755
http://dx.doi.org/10.1016/j.jcmgh.2020.01.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215182/
https://www.ncbi.nlm.nih.gov/pubmed/32004755
http://dx.doi.org/10.1016/j.jcmgh.2020.01.010

Ejemplares similares